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Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of 
bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available 
on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data 
from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis 
procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates 
were 7% and 9% (p = 0.771) and the total number of collected stem cells were 7.0 × 106 and 6.7 × 106 per kg body weight (p = 0.710) 
for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. 
The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized 
with G-CSF only.
©  2020 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine. Published by Sciendo. 
All rights reserved.
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Introduction
Multiple myeloma (MM) is a hematologic disease characterized by the 
accumulation of malignant plasma cells in the bone marrow. Triplet 
induction regimens incorporating novel agents have shown to improve 
response and prolong progression free survival (PFS) and even overall 
survival (OS) [1, 2]. Autologous hematopoietic stem cell transplantation 
(aHSCT), performed in first remission or at relapse, is standard of care 
for younger fit patients [3, 4, 5]. Successful mobilization and collection 
of peripheral blood stem cells (PBSC) are required before aHSCT. 
A target dose of 2 × 106 PBSC per kg body weight is considered a 
minimum for timely hematopoietic reconstitution, although a higher 
dose, 3 to 5 × 106 PBSC per kg body weight, is thought to be optimal 
for earlier engraftment [6, 7, 8]. A second aHSCT can be performed 
within 6 months (tandem transplant) or following progression. 
Therefore, an attempt to collect PBSC for at least two aHSCT should 
be considered. Mobilization with chemotherapy (e.g., intermediate 
doses of cyclophosphamide) and granulocyte-colony stimulating factor 
(G-CSF) is standard in most transplant centers and provides higher 
stem cell yields in fewer apheresis procedures at the cost of increased 
toxicity and less predictable onset date of apheresis in comparison 
with G-CSF mobilization only [9, 10]. On the other hand, G-CSF only 
mobilization fails to achieve the target doses of PBSC in 5–30% of 
patients [8, 11, 12, 13].
Known factors affecting stem cell mobilization are age, advanced 
disease status, extensive treatment, thrombocytopenia, prior exposure 
to irradiation, and alkylating agents [10]. Novel induction regimens 
using proteasome inhibitors (PI) and especially immunomodulatory 
drugs (IMIDs) might impact the ability to mobilize and harvest stem 
cells [14, 15]. In case of lenalidomide, a second generation IMID, there 
are data supporting its adverse impact on mobilization after prolonged 
treatment. However, there is no clear evidence of bortezomib impact 
on stem cell harvest [8, 10]. In the IFM 2005/01 trial comparing 
bortezomib and dexamethasone (VD) with vincristin, adriamycin, and 
dexamethasone (VAD), a trend to lower stem cells yields was observed 
in patients receiving bortezomib [12, 16]. G-CSF alone mobilization 
was used in this trial. On the contrary, in the HOVON-65/GMMG-HD4 
trial comparing bortezomib, adriamycin, dexamethasone (PAD) with 
VAD, all patients successfully collected stem cells for aHSCT and no 
impact of bortezomib on collection was observed [17, 18]. Of note, 
chemomobilization with cyclophosphamide and adriamycin was used 
as the mobilization procedure. There are limited and contradictory data 
on the impact of thalidomide on PBSC mobilization and collection, 
but the impact appears to be small [15, 19, 20]. In addition, the use 
of G-CSF mobilization alone is a predisposing factor for mobilization 
failure [11, 14, 15].
Triplet induction regimens incorporating bortezomib, thalidomide, 
and dexamethasone (VTD) or bortezomib, cyclophosphamide and 
dexamethasone (VCD) are current standards of care. The available 
data show a benefit of VTD compared with VCD but at the expense 
of a higher prevalence of polyneuropathy [4, 5, 21]. There are limited 
data available for the two regimens on stem cell mobilization efficacy, 
especially considering the potential negative impact of thalidomide. 
Owing to feasibility and safety reasons, we use G-CSF only 
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mobilization in MM patients at our institution, with chemomobilization 
and plerixafor reserved for mobilization failures. We undertook a 
retrospective analysis of our registry data regarding the impact of 
VTD and VCD induction on stem cell mobilization with G-CSF alone.
Patients and methods
We retrospectively analyzed data from our national registry from the 
January 1, 2014 to December 31, 2017. All patients gave written 
consent for registry data collection. A total of 72 consecutive patients 
with newly diagnosed MM who received first-line induction treatment 
with VTD or VCD and underwent stem cell mobilization with G-CSF 
were included. Patients receiving additional treatment or patients 
with relapsed/refractory disease were not included. VTD treatment 
consisted of 3 week cycles of bortezomib 1.3 mg/m2  subcutaneous 
on days 1, 4, 8, and 11, thalidomide 100 mg daily and dexamethasone 
40 mg on days 1–4 of the first cycle and once per week thereafter. 
VCD treatment incorporated bortezomib and dexamethasone in the 
same schedule as for VTD plus cyclophosphamide 500 mg/m2 on day 
1, 8, and 15. Following 3–4 cycles of induction treatment, stem cells 
were mobilized using subcutaneous filgrastim 10 mcg/kg rounded to 
the nearest available dose for 5 consecutive days. Circulating CD34+ 
cells were determined in peripheral blood on day 5, and apheresis 
was initiated at a CD34+ cell count > 20/μL. Patients with a circulating 
CD34+ cell count < 20/μL received additional filgrastim on day 6. 
Cobe spectra apheresis system was used for stem cell collection.
Outcome measures
Mobilization failure was defined as circulating CD34+ cell count 
< 20/μL up to 6 days after mobilization with G-CSF or patients with 
a yield < 2.0 × 106 CD34+ cells/kg in three apheresis procedures 
[22]. The average number of CD34+ cells was the arithmetic mean of 
CD34+ cell counts on all collection days. The number of procedures 
was the number of collection procedures per patient that were not 
mobilization failures. The number of collected cells was the total 
number of collected CD34+ cells per kg body weight of the patient. 
The dose for a single transplant of 2 × 106 CD34+ cells/kg and 
3 × 106 CD34+ cells/kg was considered the minimum and optimal 
dose, respectively. For two hematopoietic stem cell transplantations 
(HSCTs), the double dose of cells was required.
Statistical analysis
The association between the treatment and the defined variables was 
analyzed using the chi-square test or Student’s t-test for independent 
samples as required. All two-sided p values < 0.05 were considered 
statistically significant. Statistical analysis was carried out using 
SPSS v23.
Results
Twenty-eight and 44 patients received induction treatment with 
VCD and VTD, respectively. Both cohorts were balanced in terms 
of age, gender, and other disease characteristics (Tab. I). After 
data on the higher efficacy were available in 2016, VTD was the 
preferred regimen, which explains the greater number of patients in 
this group. No difference was observed in the number of induction 
cycles before mobilization between the two groups. Three patients 
received local radiation therapy to the spine and one received local 
radiation to the pelvis. One of the patients in the VTD group, who 
received radiation to the spine, failed mobilization with G-CSF 
alone. The mobilization failure rates were 7% and 9% for VCD and 
VTD, respectively. All patients failing mobilization with G-CSF later 
Table I. Patient demographics and baseline characteristics
VCD VTD
Total N 28 44
Age, years N (Range) 58 (29-69) 58 (34-70)
Male N (%) 18 (64) 30 (68)
MM stage, ISS N (%)
1 7 (25) 13 (30)
2 8 (29) 17 (39)
3 12 (43) 10 (23)
Diag. N (%)
Light Chain only 6 (21) 7 (16)
IgA 10 (36) 8 (18)
IgG 12 (43) 26 (59)
Asecretory 0 3 (7)
Induction cycles N (Median, Range) 3 (3-4) 3 (2-4)
RT before mobilization N (%) 1 (4) 3 (7)
Elev. Creat. at mobilization N (%) 2 (7) 1 (2)
Response after induction
≥ VGPR 14 (50 %) 28 (64 %)
PR 14 (50 %) 16 (36 %)
MM – multiple myeloma; Diag. – diagnosis; RT – local radiotherapy; VGPR – very good partial response; PR – partial response; Elev. Creat. – elevated creatinine
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successfully collected PBSC with chemomobilization or plerixafor. 
The average number of CD34+ cells in peripheral blood on the day 
of collection was 60.7 × 106/L and 41.1 × 106/L, and the number of 
apheresis procedures was 3 and 2 for VCD and VTD, respectively. 
The total number of collected stem cells for the VCD and VTD cohort 
was 7.0 × 106/kg and 6.7 × 106/kg recipient body weight. In total, 86% 
of patients receiving VCD induction and 75% of patients receiving 
VTD induction, collected enough stem cell for at least 2 aHSCTs. The 
median time to neutrophil engraftment was 13 days in both cohorts. 
No statistical difference was observed in the number of apheresis 
procedures, collected cells, the ability to collect a minimum and 
optimal dose for two aHSCTs, and the time to neutrophil engraftment 
between the two groups (Tab. II).
Discussion
Triplet induction therapy incorporating novel drugs is standard 
of treatment for patients with MM [1, 2]. Two commonly used 
combinations are VTD and VCD [4, 5, 21]. In our center, we use 
G-CSF only mobilization for patients with MM at first attempt. In 
patients failing to collect a sufficient number of PBSC, we switch to 
chemomobilization or the use of plerixafor. There are no published 
data on the difference between VTD and VCD regarding the 
effectiveness of G-CSF only mobilization. Owing to unresolved 
concerns that thalidomide in combination with other agents might 
impact the efficacy of G-CSF only mobilization, we decided to 
retrospectively analyze our patient registry and present the data.
The mobilization failure rates for VTD and VCD in our patient 
group were similar to some reports in the literature [13, 23]. Since 
G-CSF only mobilization and age > 60 are important predictors for 
mobilization failure, the low failure rates in our cohort of patients with 
a median age of 58 years and using G-CSF only mobilization are 
unexpectedly low [24]. This is likely due to reducing the number of 
induction cycles to a median of 4 before proceeding to mobilization 
and not using melphalan as part of the induction regimen, thereby 
reducing the toxicity to the bone marrow. Approximately 30% of 
MM patients receive radiation therapy during induction for palliation 
of bone pain or spinal cord compression [25]. Radiation therapy 
negatively influences PBSC mobilization and harvest and can even 
negatively impact overall and PFS [25, 26]. Restraint in radiotherapy 
in patients eligible for aHSCT treated with novel agents, and novel 
approaches in radiotherapy have probably decreased the number 
of mobilization failures in our patient cohort. In our patient cohort, 
only one patient received radiation therapy prior to successful 
G-CSF only mobilization (data not shown). All patients failing first 
mobilization later successfully collected a sufficient number of PBSC 
with chemomobilization or plerixafor.
The average number of CD34+ cells in peripheral blood on collection 
day was higher in the VCD cohort than in the VTD cohort; however, 
the difference was not statistically significant. The lower number of 
CD34+ stem cells can be attributed to the toxic effects of thalidomide 
on hematopoietic stem cells [27]. Studies about mice have shown 
that intermittent dosing of cyclophosphamide has a stem cell sparing 
effect [28]. Therefore, cyclophosphamide during induction has 
probably no impact on stem cell mobilization and harvesting. The 
lack of statistical difference in the number of CD34+ cells in peripheral 
blood between VTD and VCD can be attributed to the relatively small 
number of subjects in the study. However, the number of collection 
procedures and collected stem cell was the same between the 
cohorts.
Most patients in both groups collected sufficient numbers of PBSC 
for two aHSCTs. Still, the number of patients achieving an optimal 
dose for two transplants was only around 60%. Because a higher 
dose of PBSC is preferred for earlier engraftment with possible 
lower morbidity, higher numbers of PBSC should be collected [6, 
7, 8]. The relatively low number of patients collecting the optimal 
dose of stem cells for two aHSCTs (6 × 106 CD34+ cells/kg) is a 
weakness of G-CSF only mobilization, and our results are in line 
with other published results [12, 16, 29]. The addition of plerixafor 
to G-CSF improves G-CSF mobilization and can increase the 
number of patients archiving the optimal dose of PBSC for two 
aHSCTs [29].
To conclude, this study provides further data on VTD safety with 
respect to stem cell mobilization in comparison with VCD. The 
addition of thalidomide to bortezomib and dexamethasone showed 
no negative impact on stem cell mobilization and harvest in patients 
undergoing G-CSF only mobilization in our patient group.
Table II. Stem cell mobilization and harvest results 
VCD VTD
Total 28 44
Mobilization failure N (%) 2 (7) 4 (9) p = 0.771
Average CD34+ cells in blood on day of collection (Mean x 106/L, Range) 60.7 (8.4 - 431) 41.1 (6.45–132.3) p = 0.139
Number of procedures (Median, Range) 3 (0-4) 2 (0-4) p = 0.434
Collected cells (Mean x 106/kg, Range) 7.0 (0 – 12.5) 6.7 (0–13.9) p = 0.710
Minimum for two aHSCTs N (%) 24 (86) 33 (75) p = 0.275
Optimal for two aHSCTs N (%) 18 (64) 27 (61) p = 0.803
Time to Neu. engraftment (Median, Range) 13 (10-15) 13 (11–15)
aHSCT – autologous hematopoietic stem cell transplant; Neu. – neutrophil
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